Omeros (NASDAQ:OMER) Coverage Initiated at D. Boral Capital

Analysts at D. Boral Capital assumed coverage on shares of Omeros (NASDAQ:OMERGet Free Report) in a research note issued on Monday, MarketBeat.com reports. The brokerage set a “buy” rating and a $36.00 price target on the biopharmaceutical company’s stock. D. Boral Capital’s target price would indicate a potential upside of 260.00% from the company’s current price.

OMER has been the subject of a number of other reports. RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. Rodman & Renshaw initiated coverage on shares of Omeros in a report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price target for the company. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Thursday, December 19th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Get Our Latest Stock Analysis on Omeros

Omeros Trading Down 1.1 %

Omeros stock opened at $10.00 on Monday. The firm has a market cap of $579.50 million, a PE ratio of -4.33 and a beta of 1.97. Omeros has a 12 month low of $2.61 and a 12 month high of $13.60. The stock’s 50 day simple moving average is $7.21 and its two-hundred day simple moving average is $5.24.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Barclays PLC raised its position in shares of Omeros by 121.3% in the third quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock valued at $376,000 after buying an additional 51,873 shares during the last quarter. Geode Capital Management LLC raised its holdings in Omeros by 0.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock valued at $5,318,000 after acquiring an additional 6,839 shares during the last quarter. MML Investors Services LLC lifted its stake in Omeros by 19.2% in the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 3,000 shares in the last quarter. Jane Street Group LLC boosted its holdings in shares of Omeros by 15.9% during the 3rd quarter. Jane Street Group LLC now owns 58,277 shares of the biopharmaceutical company’s stock worth $231,000 after purchasing an additional 8,010 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new stake in shares of Omeros in the third quarter valued at approximately $305,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

(Get Free Report)

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

Further Reading

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.